Pathology of Cardiac Amyloidosis

Introduction

Cardiac amyloidosis is a form of infiltrative cardiomyopathy caused by the deposition of amyloid fibrils in the heart. This condition results in structural and functional abnormalities of the heart, leading to progressive heart failure and other complications. Below is a detailed description of the pathology of cardiac amyloidosis, organized under several subheadings.

What Is Amyloidosis?

Amyloidosis refers to a group of diseases characterized by the extracellular deposition of amyloid fibrils, which are insoluble protein aggregates. These fibrils are composed of misfolded proteins that adopt a beta-sheet configuration, making them resistant to degradation. In cardiac amyloidosis, amyloid deposits primarily affect the myocardium, leading to significant alterations in the structure and function of the heart. Amyloid fibrils can be derived from various precursor proteins, with the most common being immunoglobulin light chains (AL amyloidosis) and transthyretin (ATTR amyloidosis).

What Are the Types of Cardiac Amyloidosis?

There are several types of cardiac amyloidosis, each associated with different precursor proteins:

• AL (Primary) Amyloidosis: This type results from the deposition of amyloid fibrils derived from immunoglobulin light chains, typically produced by an abnormal clonal population of plasma cells in conditions such as multiple myeloma.

• ATTR (Transthyretin) Amyloidosis: This form is associated with the deposition of transthyretin, a transport protein for thyroxine and retinol. ATTR amyloidosis can be hereditary due to mutations in the TTR gene or acquired (wild-type), which is more common in elderly individuals.

• Secondary (AA) Amyloidosis: Although rare in the heart, this type results from the deposition of serum amyloid A protein, usually in the context of chronic inflammatory conditions.

What Is the Pathogenesis of Cardiac Amyloidosis?

The pathogenesis of cardiac amyloidosis involves the misfolding of specific proteins, leading to the formation of insoluble amyloid fibrils. These fibrils are deposited in the extracellular matrix of the myocardium, where they disrupt normal cellular architecture and function.

• Protein Misfolding: The precursor proteins undergo structural changes, often due to genetic mutations, leading to the formation of amyloid fibrils with a characteristic beta-sheet structure.

• Fibril Deposition: The amyloid fibrils are deposited extracellularly in the myocardium, where they accumulate over time, leading to progressive tissue infiltration.

• Tissue Damage: The deposition of amyloid fibrils disrupts the normal function of the myocardium, leading to stiffness, impaired contractility, and heart failure. The infiltration of amyloid into the conduction system can also lead to arrhythmias and conduction abnormalities.

What Is the Histopathology of Cardiac Amyloidosis?

Histopathological examination of the myocardium in cardiac amyloidosis reveals characteristic findings:

• Gross Pathology: The heart is typically enlarged and firm, with a rubbery consistency. The ventricular walls may be thickened, leading to a restrictive cardiomyopathy. The atria may also be dilated.

• Microscopic Features: Amyloid deposits appear as amorphous, eosinophilic material in the extracellular matrix, particularly around the myocardial fibers and blood vessels. The deposits may be diffuse or nodular. On Congo red staining, amyloid deposits show apple-green birefringence under polarized light, which is a diagnostic hallmark.

• Immunohistochemistry: Immunohistochemical staining can be used to identify the specific type of amyloid fibril, such as kappa or lambda light chains in AL amyloidosis or transthyretin in ATTR amyloidosis.

What Is the Molecular Pathology of Cardiac Amyloidosis?

The molecular basis of cardiac amyloidosis involves the production and deposition of amyloidogenic proteins:

• AL Amyloidosis: The underlying cause is often a plasma cell dyscrasia, where abnormal clonal plasma cells produce excess light chains that misfold and aggregate into amyloid fibrils.

• ATTR Amyloidosis: Hereditary ATTR amyloidosis is caused by mutations in the TTR gene, which increase the propensity of transthyretin to misfold and form amyloid. Wild-type ATTR amyloidosis occurs without a genetic mutation, often in older adults, due to age-related changes in transthyretin.

• AA Amyloidosis: This type is associated with chronic inflammation, leading to the overproduction of serum amyloid A protein, which can misfold and deposit as amyloid.

What Are the Clinical Manifestations of Cardiac Amyloidosis?

The clinical presentation of cardiac amyloidosis is highly variable and depends on the extent and location of amyloid deposition:

• Heart Failure: The most common manifestation, heart failure in cardiac amyloidosis is typically of the restrictive type, characterized by preserved ejection fraction and diastolic dysfunction. Patients may present with symptoms of congestive heart failure, including dyspnea, fatigue, and edema.

• Arrhythmias: Amyloid deposition in the conduction system can lead to a variety of arrhythmias, including atrial fibrillation, atrioventricular block, and ventricular arrhythmias. Sudden cardiac death is a significant risk.

• Conduction Abnormalities: Conduction system involvement can result in bradyarrhythmias and heart block, necessitating the use of pacemakers.

• Valvular Disease: Amyloid deposits can infiltrate the cardiac valves, leading to valvular thickening and regurgitation, particularly of the mitral and tricuspid valves.

• Pericardial Involvement: Although less common, amyloid infiltration of the pericardium can lead to pericardial effusion and, rarely, constrictive pericarditis.

What Is the Diagnosis of Cardiac Amyloidosis?

The diagnosis of cardiac amyloidosis involves a combination of clinical, imaging, and biopsy findings:

• Echocardiography: Echocardiographic findings in cardiac amyloidosis typically show increased ventricular wall thickness, a sparkling or granular appearance of the myocardium, and diastolic dysfunction.

• Cardiac Magnetic Resonance Imaging (MRI): Cardiac MRI can reveal late gadolinium enhancement, which is indicative of amyloid infiltration. T1 and T2 mapping techniques can also assess the extent of myocardial involvement.

• Endomyocardial Biopsy: This is the gold standard for diagnosing cardiac amyloidosis. Congo red staining of the biopsy tissue, followed by polarization microscopy, can confirm the presence of amyloid. Further immunohistochemical studies can identify the type of amyloid.

• Biomarkers: Serum and urine tests for free light chains are useful in AL amyloidosis. In ATTR amyloidosis, genetic testing for TTR mutations can confirm hereditary cases.

What Is the Prognosis of Cardiac Amyloidosis?

The prognosis of cardiac amyloidosis is generally poor, particularly in AL amyloidosis, where the disease is often rapidly progressive. Factors influencing prognosis include the type of amyloid, the extent of cardiac involvement, and the presence of other organ involvement. Early diagnosis and treatment are crucial for improving outcomes.

What Is the Treatment for Cardiac Amyloidosis?

The treatment of cardiac amyloidosis varies depending on the type of amyloid involved:

• AL Amyloidosis: Treatment is focused on reducing the production of amyloidogenic light chains, typically with chemotherapy regimens similar to those used in multiple myeloma. Autologous stem cell transplantation is an option for selected patients. Supportive care for heart failure and arrhythmias is also essential.

• ATTR Amyloidosis: In hereditary ATTR amyloidosis, liver transplantation was traditionally used to reduce the production of mutant transthyretin. However, newer therapies, such as transthyretin stabilizers (e.g., Tafamidis) and gene-silencing therapies (e.g., Patisiran), have shown promise in reducing disease progression. Supportive care for cardiac symptoms is also important.

• Secondary Amyloidosis: Management focuses on treating the underlying inflammatory condition and providing supportive care for cardiac symptoms.

Conclusion

Cardiac amyloidosis is a complex and often life-threatening condition characterized by the deposition of amyloid fibrils in the heart. Understanding the pathophysiology, clinical manifestations, and diagnostic approaches is crucial for managing this disease effectively. Despite recent advances in treatment, early detection remains key to improving patient outcomes. Continued research into the molecular mechanisms of amyloidogenesis and the development of targeted therapies holds promise for the future management of this challenging condition.